TABLE 1.
NcRNA | Model study | Expression | Target gene/pathway | Type of ncRNA | Biological function | References |
---|---|---|---|---|---|---|
miR-21, miR-24 and miR-421 | In silico and in vitro | Up | ATM/ATR/H2AX | Oncogene | Recognition and repair of DNA damage | Manoel-Caetano et al. (2019) |
miR-192 and miR-215 | In vivo and in vitro | Up | SET8 and p53 | Oncogene | Promotes DNA damage repair and promotes progression of GC | Zhang et al. (2020) |
miR-129-3p | In vitro | Down | SUMO-activating enzyme subunit 1 (SAE1) | Tumor suppressor | Induces more DNA damage and cell apoptosis, and inhibits GC cell proliferation, migration and invasion | Zhang et al. (2019) |
lncRNA GAS5 | Mathematical model | Down | ATM/p38 MAPK and miR-34c | Tumor suppressor | Stimulate of DNA damage and enhances the radiosensitivity of GC | Gupta et al. (2022) |
lncRNA FOXD2-AS1 | In vitro | Up | SETD1A | Oncogene | Promotes DNA damage repair and reduces the radiosensitivity of GC | Guo et al. (2022) |
lncRNA MDC1-AS | In vivo and in vitro | Up | MDC1 | Oncogene | Promotes DNA damage repair and significantly inhibits cell proliferation and metastasis | Qin et al. (2018) |
Circular RNA AKT3 | In vivo and in vitro | Up | PIK3R1 | Oncogene | Promotes DNA damage repair and inhibits the apoptosis of GC cells | Huang et al. (2019) |
Abbreviations: ATM, Ataxia-telangiectasia mutated; ATR, Ataxia telangiectasia and Rad3-related protein; SAE1, SUMO-activating enzyme subunit one; MAPK, Mitogen-activated protein kinase; MDC, Macrophage-derived/CCL22 chemokine; PIK3R1, Phosphatidylinositol 3-kinase regulatory subunit alpha; GAS5, Growth arrest-specific five; FOXD2-AS1, Forkhead box D2 adjacent apposite strand RNA, one; MDC1-AS, Mediator of DNA, damage checkpoint protein one; AKT3, AKT, serine/threonine kinase 3.